The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.

Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.

Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.

Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.

Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.

What Are The Symptoms Measles?

Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.

Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.

Why It Is Important To Get Vaccinated?

According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.

Who Should Get Vaccinated?

Kids Need Two Shots

All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.

College Students Need to Be Protected

Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.

Adults Need at Least One Shot

Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.

Travelers Need to Be Extra Careful

Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.

Healthcare Workers Must Be Immune

People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.

Women Thinking About Having Babies

Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.

While psychedelics—psychoactive substances known to alter perception and mood—have long been sidelined, the US President Donald Trump and his administration are bringing them back to mainstream treatment.

In a significant push, Trump last week signed an executive order where he directed the Food and Drug Administration (FDA) to expedite a review of psychedelic drugs, including ibogaine.

The executive order signed on Saturday is designed to fast-track both research on and access to these drugs. It also includes a $50 million investment in state governments to study how psychedelics might help people struggling with mental health illnesses.

Emerging research shows psychedelics can help improve mental health, especially in conditions where traditional treatment approaches have not been useful. However, these drugs also come with several health risks that cannot be overlooked.

According to FDA Commissioner Dr. Marty Makary, ibogaine could “soon” be on track to receive FDA approval once the agency reviews data from late-stage clinical trials, CNN reported.

“Once we have them in-house, we’ll be issuing National Priority Vouchers for a review within one to two months instead of the standard one-year time frame. And that’s because this is a national priority,” Makary said.

“These are potentially promising treatments,” he said. “We’ll see how the data reads out when we get the applications, but we don’t want to waste any time, because this is an urgent matter given the mental health crisis,” the Commissioner said.

Makary noted that if ibogaine gets approved, these will be "given in a controlled, supervised setting in a hospital.”

What Is Ibogaine?

Historical evidence suggests that ibogaine was first used by the Pygmy people in Central Africa as a sacred medium, believed to be a gift from God, which allowed them to reconnect with the divine and the dead.

It was later, during the colonial period, that the communities in the region used the compound for unity and shared experience.

Also read: RFK Jr. And Trump Cabinet Want Psychedelics To Be Legal After FDA Shut Down; What This Means For The Controversial Drug?

It was in 1962 that Ibogaine was first seen as a potential treatment for substance-related disorders by researchers in the US. While studies back then showed promising results, psychedelics were considered controversial and, broadly, “abandoned” by researchers.

Since 1967, the Drug Enforcement Administration (DEA) in the US has classified ibogaine as a Schedule I controlled drug. Schedule I substances are those that currently have no accepted medical use and have a high potential for abuse. They are also illegal to use.

However, in recent years, ibogaine has garnered several high-profile supporters, including former Texas Gov. Rick Perry, former Sen. Kyrsten Sinema of Arizona, and podcast host Joe Rogan.

Is Ibogaine Beneficial? What Are The Health Risks?

As per preliminary research, ibogaine has the potential to alter certain brain pathways, which can improve some mental health conditions, including PTSD, anxiety, or depression.

The executive order is a “great step,” Dr. Kirsten Cherian, a researcher at Stanford University who led a landmark study on ibogaine, was quoted as saying to CNN. Cherian added that the order may open the door to offering the treatment in US research facilities.

“The first step is to be able to do the research at home,” she said. “And it could open up a lot of research possibilities. It is kind of an exciting time.”

As per the Legislative Analysis and Public Policy Association, Ibogaine’s effects are prolonged, beginning a half hour to three hours after ingestion and can last more than 24 hours.

Individuals who have used ibogaine report experiencing a dream-like state with visual and sensory distortions. After the peak effects of the substance abate, users report going through a period of reflection and report having residual effects lasting up to 72 hours that include heightened awareness, mild stimulation, and disturbed sleep.

The hallucinogen is also known to raise the risk of abnormal heart rhythms, which could cause vomiting. This makes the use of the substance particularly risky for individuals with preexisting heart problems. There has been a total of 33 ibogainerelated deaths publicly reported in scientific literature to date.

In a groundbreaking move, the US Food and Drug Administration has approved the first-ever dual adeno-associated virus (AAV) vector-based gene therapy to treat hearing loss.

AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound hearing loss.

Developed by American Biotechnology company Regeneron, Otarmeni has been approved for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency more than 90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene.

To date, no disease-modifying treatments exist for OTOF-related deafness.

“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” said FDA Commissioner Marty Makary, in a statement.

“Through the national priority voucher pilot program, the agency is accelerating therapies for rare diseases with unmet medical needs while proving we can successfully review even the most complex submissions—such as novel dual vector gene therapies and combination products requiring coordination across multiple offices and centers—in significantly shortened timeframes,” Markary added.

Importantly, the company has announced that it will offer the therapy free of cost to qualifying individuals, at least during the initial rollout phase. The company cited its commitment to accessibility and patient impact as key reasons behind the decision.

How Otarmeni Works

Hearing loss affects over 430 million people worldwide, with a significant portion caused by genetic mutations. Genetic mutations cause about half of congenital hearing loss. Variants in the OTOF gene account for 2 per cent to 8 per cent of inherited, non-syndromic cases.

Until now, treatment options have largely been limited to hearing aids or cochlear implants, which assist hearing but do not address the underlying cause.

Genetic mutations cause about half of congenital hearing loss. Variants in the OTOF gene account for 2 per cent to 8 per cent of inherited, non-syndromic cases.

The OTOF gene is responsible for producing otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. Without it, sound cannot be processed, resulting in profound deafness.

Otarmeni is for patients with preserved outer hair cell function and no prior cochlear implant in the same ear.

Otarmeni includes a dual adeno-associated virus serotype 1 (AAV1) vector gene therapy administered as a single dose per ear surgically into the cochlea via a syringe and catheter provided in the Administration Kit and connected to an infusion pump.

The therapy delivers a functional copy of the OTOF gene to inner hair cells to restore otoferlin production and auditory signaling.

Are There Any Side Effects

The FDA noted that the common side effects included middle ear infection, nausea, dizziness, and procedural pain. Providers should monitor for surgical complications. It noted that the therapy is not recommended for patients with anatomy that prevents safe access to the inner ear.

The FDA approval comes after a landmark study, published in the New England Journal of Medicine, showed the benefits of hearing restoration. In trials, 80% of children aged 10 months to 16 years showed real improvement in just 24 weeks. This is not expected in the natural history of the disease without intervention.

For the past two days, Delhi locals have been waking up to extreme heatwave conditions. The India Meteorological Department (IMD) issued a warning of an extreme heatwave for Friday and Saturday, and we are now on day 2. On Friday, temperatures in the national capital were recorded at 43.1 degrees Celsius and 41.9 degrees Celsius. At the Ridge station and Lodhi Road, a high of 41.8 degrees was recorded, which met the criteria for heatwave conditions. Citing this, the IMD issued a yellow alert for Saturday, forecasting isolated heatwave conditions in the city. With this comes an increased risk of heat stress.

What is heat stress?

Heat stress refers to a state wherein the body absorbs more heat from the environment or produces heat through exertion that overwhelms the body's natural cooling system. This is caused by humidity, high temperatures, or exercise, leading to symptoms like headaches, dizziness, and, in extreme cases, heatstroke.

Heat stress occurs when the body is exposed to radiant heat, high air temperature, physical exertion, high humidity, or low air movement. It harms the body's ability to maintain a normal core temperature, thereby resulting in dehydration and cardiovascular strain. It is advised to wear protective clothing and drink plenty of water to stay hydrated.

What are the signs of heat stress?

Dr Anirban Chattopadhyay, Senior Consultant, Critical Care Medicine, CK Birla Hospitals, CMRI, in an interaction with Health and Me, spoke about the symptoms of heat stress. The expert said, “As the summer season begins and the sunlight is now scorching, heat and related symptoms increase. One of the early symptoms of heat exhaustion is headache, light-headedness, dizziness, and brain fog. This happens because the brain is temperature-sensitive. That is why patients often experience a headache when temperatures rise. This occurs due to vasoconstriction. One may experience dizziness and brain fog because the brain cannot withstand high levels of heat. These are the early symptoms of heat stress.”

When heat stress or prolonged heat exposure continues, it can progress to a more serious condition. This may even lead to a comatose state, known as heatstroke. Therefore, avoid direct sunlight exposure. If possible, stay indoors during peak hours, from 12 pm to 3 pm. Drink plenty of water to keep yourself hydrated, and consume electrolyte-containing fluids to maintain balance. When going out, use umbrellas and sunglasses, and wear breathable fabrics like cotton.

Heatwave across Central and North India

The heatwave is not restricted to the national capital—it is currently affecting northern and central states such as Madhya Pradesh, Rajasthan, Bihar, Chhattisgarh, Chandigarh, and Haryana. The conditions are likely to continue until April 27, with low chances of relief in the coming week.